Onasemnogene Abeparvovec Intravenous (Zolgensma®) Service & Onasemnogene Abeparvovec Intrathecal (OAV101 IT) Service
Purchaser
NHS England
Country
United Kingdom
Notice published
4 Jun 2026
Tenqual indexed
5 Jun 2026
Closing date
Not listed
Source ID
Docs found
—
Save this notice and create a free tender alert for similar public opportunities.
- Create one free tender alert.
- See a short explanation of why each tender matches.
- Upgrade later when you want help planning and writing the bid.
Tender summary
Onasemnogene abeparvovec intravenous (Zolgensma®) is a one-time, in vivo gene replacement therapy, for use in babies aged 12 months and under, that utilises an adeno-associated virus serotype 9 (AAV9) vector, modified to contain a functional copy of the human SMN1 gene. It is administered intravenously, allowing the vector to deliver the gene into motor neurones and peripheral tissues, enabling the sustained expression of survival motor neuron (SMN) protein, which is deficient or mutated in individuals with SMA. Onasemnogene abeparvovec intrathecal (OAV101 IT) is a one-time in vivo gene replacement therapy for patients with SMA, proposed to treat individuals with SMA aged 2 years and over. This intrathecal injection will be used to treat a distinct cohort of SMA patients to Zolgensma. It will be assessed via NICE’s technology appraisal programme, with an expected final guidance publication date in late 2026.
What to check before bidding
- Issued by NHS England.
- Located in United Kingdom.
- Source notice 053026-2026 on uk.
- Notice published 4 Jun 2026; Tenqual indexed it 5 Jun 2026.
- No closing date is listed yet.
- Create a free tender alert to catch similar opportunities before the deadline pressure starts.